Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

2025--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains ... Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study will ...

and President of Bayer’s Pharmaceuticals Division. "Our new operating model is visibly becoming a key enabler to drive growth and efficiency gains." Topline improved and poised for future growth Bayer ...